

Review on Pharmacovigilance

S. R. Mane, S. K. Bias, S. R. Khulape

Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India

Abstract: *Pharmacovigilance plays a significant part in the healthcare system by keeping track of drug interactions and the impact of those interactions on the human body. The purpose and methods of pharmacovigilance, the goals of the Pharmacovigilance Program of India (PvPI), the list of national adverse drug monitoring centres (AMCs), and their roles are all outlined in this article. The Indian Pharmacopoeia Commission, which serves as the country's national coordination centre for the pharmacovigilance programme, may prioritise promoting safe drug usage. This article discusses the significance of good clinical practise from the perspective of Indian clinical research, while defining and outlining the GCP Protocol designing for clinical trial, Process of Clinical Trial Application (CTA), Elements of the non-clinical and clinical safety specification, Design and conduct of clinical trial, and Goals and Objectives of the GCP Protocol.*

Keywords: Pharmacovigilance, Clinical Trial, New Drugs and Clinical trials Rules 2019, India, ICH-GCP, Regulatory Applications, PvPI

REFERENCES

- [1]. Kesharwani V, Farooqui M, Kushwaha N, Singh R, Jaiswal P. AN OVERVIEW ON PHARMACOVIGILANCE: A KEY FOR DRUG SAFETY AND MONITORING. JDDT [Internet]. 11Sep.2018 [cited 12Dec.2022];8(5):130-5.
- [2]. A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA Available online at www.ijdra.com REVIEW ARTICLE 1 Prajapati Vishal*, 1Goswami Rahulgiri, 1Makvana Pratik, 2Badjatya Jitendra Kumar 1L.J. Institute of Pharmacy, S.G. Highway, Ahmedabad, Gujarat, India. 2Montajat Pharmaceuticals Co. Ltd., Dammam, KSA
- [3]. International Conference of Harmonization Good Clinical Practice ICH GCP by Tamer Hifnawy Professor of public health and community medicine.
- [4]. The New Drugs and Clinical Trials Rules, 2019 By Dr. V.G. SOMANI Drugs Controller General (India), CDSCO Ministry of Health & Family Welfare, Government of India
- [5]. New drug and clinical trial rules, 2019 By Dilip Kawane
- [6]. A Text Book Of "Industrial Pharmacy" By Dr.K.P.Sam path Kumar, Dr.Debjit Bhowmik, Rishabh Bhanot, Shambaditya Goswami, Nirali Prakashan Page no.3.18 -3.20
- [7]. Karnik, K.S., Sarkate, A.P., Tiwari, S.V. et al. Design, synthesis, biological evaluation and in silico studies of EGFR inhibitors based on 4-oxo-chromane scaffold targeting resistance in non-small cell lung cancer (NSCLC). Med Chem. Res 31, 1500–1516 (2022). <https://doi.org/10.1007/s00044-022-02929-4>
- [8]. Ankur Rohilla, Nishant Singh, Vipin Kumar, Mohit Kumar Sharma, Amarjeet Dahiya, Ashok Kushnoor; Pharmacovigilance: Needs and Objectives, J. Adv. Pharm. Edu. & Res. 2012; 4: 201-205
- [9]. National Coordinating Centre (NCC) ADR Monitoring Centres-AIIMS
- [10]. A REVIEW ON PHARMACOVIGILANCE AND ITS IMPORTANCE I. Lakshmi Anusha*, M. Aashritha, K. Teja and R. Sridhar Department of Pharmacy Practice, Hindu College of Pharmacy, (A.P), India